<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="2000" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="1126" end="1127"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="1132" end="1143"/>
    <type:PFSMean xmi:id="21" sofa="6" begin="1311" end="1314"/>
    <type:PFSMean xmi:id="25" sofa="6" begin="1319" end="1330"/>
    <type:PFSMean xmi:id="29" sofa="6" begin="1357" end="1360"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1365" end="1374"/>
    <type:ORR xmi:id="37" sofa="6" begin="1714" end="1717"/>
    <type:ORR xmi:id="41" sofa="6" begin="1722" end="1725"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: The aim of this study is to evaluate the influence of germline vascular &#13;&#10;endothelial growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the&#13;&#10;anti-VEGF antibody bevacizumab (Bev) in metastatic colorectal cancer (MCRC)&#13;&#10;patients.&#13;&#10;METHODS: Forty MCRC patients eligible for a first-line therapy were enrolled in&#13;&#10;this prospective trial and treated with FOLinate/Fluorouracil/Irinotecan&#13;&#10;(FOLFIRI)?+?Bev (male/female?=?22:18, age (median)?=?61 years). Eight VGPs within&#13;&#10;the promoter/5'UTR region were evaluated in patient blood samples. Primary&#13;&#10;endpoint was association between VGPs and median progression-free survival&#13;&#10;(mPFS). Overall radiological response rate (ORR), overall survival (OS), and&#13;&#10;toxicity were assessed as secondary outcomes.&#13;&#10;RESULTS: VGPs -2578, -1512, -1451, -1411, and -460 were in complete linkage&#13;&#10;disequilibrium and therefore analyzed as haplotype (two variants: Haplo1: A-18 bp&#13;&#10;insertion-T-4G-C and Haplo2: C-18 bp deletion-C-5G-T, respectively). Seventeen&#13;&#10;patients Haplo2/Haplo2 had significantly shorter mPFS compared to 23 patients&#13;&#10;Haplo1/Haplo1 or Haplo1/Haplo2 (mPFS, 9 vs. 15.4 months, respectively, p?=?0.02; &#13;&#10;hazard ratio (HR), 2.64). Also, VGPs -152 (G/G vs. G/A?+?A/A) and -1154 (G/G vs. &#13;&#10;G/A?+?A/A) were significantly associated with PFS (mPFS, 8.9 vs. 15.4 months,&#13;&#10;p?=?0.007; HR, 3.53 and 9.8 vs. 16 months, p?=?0.03, HR, 2.32, respectively). In &#13;&#10;the multivariate analysis including also biochemical variables known to influence&#13;&#10;prognosis, VGP -1154 retained an independent predictive value for mPFS (G/G over &#13;&#10;G/A?+?A/A?=?HR, 4.43; p?=?0.02). With regard to ORR, only VGP -634 was&#13;&#10;significantly associated with response (G/G vs. G/C?+?C/C?=?64% vs. 14%,&#13;&#10;p?=?0.03). No significant influence on OS and toxicity by the investigated VGPs&#13;&#10;was observed.&#13;&#10;CONCLUSIONS: Although these data need to be confirmed in larger trials,&#13;&#10;investigation of germline VGPs may help identify patients who are more sensitive &#13;&#10;to anti-VEGF agents."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33 37 41"/>
</xmi:XMI>
